Biomedical cannabis company, Cannabotech, says its products eliminated “over 90 per cent” of colon cancer cells in early studies.
Cannabotech, which is currently developing cancer products based on cannabis and mushroom extracts, has announced cell model study results, showing that its Integrative-Colon products killed over 90 per cent of cancer cells.
The study was conducted by Cannabotech’s scientific team, including Professor Tami Peretz, a senior oncologist at Hadassah Ein Kerem Hospital in Israel and Dr Isaac Angel, a pharmacologist specialising in drug development.
They examined the effect of Cannabotech’s Integrative Colon products on various colon cancer subtypes, representing common molecular changes in cancer variations.
The unique products’ composition was also compared with the activity of each cannabinoid separately. Results showed that Cannabotech’s products were significantly more effective as a composition, than each cannabinoid individually.
Cannabotech claims that to achieve effective treatment in the oncology field, it is necessary to build a defined, accurate and science-based formula, which cannot be obtained in any cannabis strain that exists in nature.
The study also demonstrated the different effects of each cannabinoid on distinct subtypes of colon cancer, highlighting the need for personalised medical care for patients.
The mushroom extracts contain an enriched and high concentration of an active substance called PSK, extracted from the Trametes mushroom, which is known for its anti-cancer properties and has been approved as an oncology treatment in Japan, Taiwan and South Korea.
During the next stages of development, the formula’s effectiveness will be examined in combination with standard chemotherapies.
The treatment is expected to be launched in Israel, US and the UK in late 2022.
Earlier this year, Cannabotech announced that its products designed to target pain and inflammation, reduced symptoms by more than 80 per cent.
Professor Peretz, senior oncologist, commented: “Colon cancer is one of the most common tumours today, with a significant proportion of patients currently treated with integrative therapies, in combination with traditional methods, including the administration of medical cannabis.
“Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients. The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”
Isaac Angel, pharmacological consultant, added: “The significant synergistic effect demonstrated by the combination of active ingredients, eliminated over 90 per cent of all types of cancer cells used in the study.
“Furthermore, this was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect, whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products and highlight the need for medical care customisation. We shall continue to work to provide a cure for patients.”